<code id='7AAB147E46'></code><style id='7AAB147E46'></style>
    • <acronym id='7AAB147E46'></acronym>
      <center id='7AAB147E46'><center id='7AAB147E46'><tfoot id='7AAB147E46'></tfoot></center><abbr id='7AAB147E46'><dir id='7AAB147E46'><tfoot id='7AAB147E46'></tfoot><noframes id='7AAB147E46'>

    • <optgroup id='7AAB147E46'><strike id='7AAB147E46'><sup id='7AAB147E46'></sup></strike><code id='7AAB147E46'></code></optgroup>
        1. <b id='7AAB147E46'><label id='7AAB147E46'><select id='7AAB147E46'><dt id='7AAB147E46'><span id='7AAB147E46'></span></dt></select></label></b><u id='7AAB147E46'></u>
          <i id='7AAB147E46'><strike id='7AAB147E46'><tt id='7AAB147E46'><pre id='7AAB147E46'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          Wikipedia

          author:focus    - browse:53
          Scorecard
          Ryan Pierse/Getty Images

          Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter:

          In December, Vertex Pharmaceuticalsannounced results from a mid-stage clinical trial showing its experimental, non-opioid drug reduced pain in people with diabetes who have chronic pain. This quarter, the company will read out results from Phase 3 studies of the same pain drug, called VX-548, in people with acute pain following surgery.

          advertisement

          The next big test of Alnylam Pharmaceuticals’pipeline of RNA-interference medicines looms with the outcome of a Phase 3 study called HELIOS-B that is investigating vutrisiran as a treatment for ATTR-CM, a progressive disease that leads to heart failure.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          hotspot